In this important podcast, Alan K. Davis, PhD, of Johns Hopkins University’s Center for Psychedelic and Consciousness Research, talks about his clinical research studying the effects of psilocybin for those who suffer from depression.
Dr. Davis provides a thorough overview of his research. He is a guide for psychedelic- assisted psychotherapy for those who suffer from depression. The Johns Hopkins University researcher’s work is centered on psychedelic research—clinical trials with psilocybin for people who have depression. Dr. Davis explains how psilocybin can potentially improve mental health. And progress seems to be happening, for as many as 50% of their study’s participants experienced a complete eradication of their depression after just one month of treatment. Dr. Davis states that a “good number” of those people are still free of their depression symptoms at the three and six month marks, so researchers are hopeful.
Dr. Davis provides an outline of how their treatment process works and why psychotherapy is an important part. He discusses upcoming trials and the necessary data that the FDA will require before they will approve psilocybin as a drug that can be prescribed by psychiatrists. Dr. Davis discusses legislative changes, and the DEA’s role.
The research doctor discusses the pathways that allow psilocybin to act. He explains how psilocybin takes action on an important neurotransmitter in the brain—serotonin. Dr. Davis explains how serotonin regulates mood, appetite, and sleep, and why psilocybin is perhaps a good option for depression, as it seems to help stabilize the aforementioned in